Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabedersen vs Standard Chemotherapy in Recurrent/Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
NCT00761280Phase 3Terminated
- Sponsor
- Isarna Therapeutics
- Start
- Dec 2008
- Primary completion
- Feb 2012
- Countries
- 16
01
Overview
A Phase 3 trial of trabedersen in anaplastic astrocytoma (AA), glioblastoma (GBM), sponsored by Isarna Therapeutics. Started Dec 2008; status: terminated.
02
Drugs
trabedersen
03
Conditions
anaplastic astrocytoma (AA)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00761280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00761280.